Testing two medications together for bowel inflammation and weight management

This trial is testing whether mirikizumab combined with tirzepatide can reduce ulcerative colitis symptoms and help people lose weight more effectively than mirikizumab alone. Ulcerative colitis is a condition causing inflammation and damage to the colon, and this study focuses on people who haven't responded well to other treatments. The research team wants to see if treating both the bowel inflammation and weight together leads to better overall health outcomes.

Many people with ulcerative colitis also struggle with excess weight, and existing treatments don't always work well for everyone. This trial explores whether combining a medication designed to reduce bowel inflammation with one designed to aid weight loss could address both problems at once, potentially improving quality of life for patients who haven't benefited from other options.